"The Pivot submission is an exciting milestone in our mission to deliver a differentiated tubeless patch pump experience to those who want a simple pump to manage the treatment of diabetes," commented ...

Detailed price information for Modular Medical Inc (MODD-Q) from The Globe and Mail including charting and trades.

PARSIPPANY, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced it has ...

One of the diabetes market’s newest spinoffs is set to undergo a significant change. Embecta, which was spun out of Becton Dickinson in April of 2022, is instituting a restructuring plan that includes ...

SAN DIEGO, CA / ACCESS Newswire / November 17, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 ...

Embecta Corp., a global diabetes care company, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration for its disposable insulin delivery system. Indicated for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Higher consumption of rye, oats and fruits increased the ...

Investors poured a further $13 million into Vicentra BV for Kaleido, its insulin patch pump system, taking the total raised in the company’s series D financing round to $98 million. The funds come ...

The MarketWatch News Department was not involved in the creation of this content. Insulin Delivery Devices Market Surges to USD 43.11 Billion by 2033 as Smart Pumps, Automated Systems & Digital ...

The medical-technology company disclosed the cancellation Wednesday in a brief filing with the U.S. Securities and Exchange Commission that offered few details. "Medtronic has exercised its rights to ...

While 9 out of 10 people with diabetes are living with T2D, many of the automated insulin delivery solutions currently on the market were designed for people living with T1D. 300-unit insulin ...

Submission delayed by U.S. government shutdown; initial FDA questions expected during Q4 2025 "The Pivot submission is an exciting milestone in our mission to deliver a differentiated tubeless patch ...